Literature DB >> 10525978

A retrospective long-term analysis of the epidemiology and features of drug-induced headache.

S Evers1, B Suhr, B Bauer, K H Grotemeyer, I W Husstedt.   

Abstract

Drug-induced headache is well known to result from the abuse of compounds taken for the treatment of primary headache. The features of drug-induced headache depend on various features including the availability of drugs, the regional health system, and psychogenic factors of the patients. We performed a retrospective study on a series of 257 consecutive German patients presenting with drug-induced headache during the period 1983-1996. Our aim study was to evaluate the demographic features, the frequency of various drugs used, in particular of ergotamine derivates, and changes in these features during the study period. The frequency of drug-induced headache among all headache patients was 8%, with a female preponderance of 81%. Drug-induced headache occurred in all age groups, predominantly in migraine patients (35%). The mean number of substances used was 2.7, mainly, acetaminophen (47.9%), ergotamine tartrate (45%), and combined analgesics (56%). We did not find a significant difference between the associations with ergotamine tartrate and dihydroergotamine, although the latter was taken less frequently. Comparing the early and late years of our study period, there were no changes in the frequency of drug-induced headache (8% versus 7%), although changes in the frequency of some drugs changed (barbiturates, ergotamine tartrate, and codeine intake decreased whereas nonsteroidal anti-inflationary drugs, combined analgesics, and sumatriptan intake increased). Our data suggest that changes in drug availability and the introduction of classification criteria and treatment recommendations did not have a major impact on the frequency of drug-induced headache.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10525978     DOI: 10.1007/s004150050458

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  7 in total

Review 1.  A Critical Evaluation on MOH Current Treatments.

Authors:  Andrea Negro; Martina Curto; Luana Lionetto; Simona Guerzoni; Luigi Alberto Pini; Paolo Martelletti
Journal:  Curr Treat Options Neurol       Date:  2017-08-15       Impact factor: 3.598

Review 2.  Medication Overuse Headache: The Reason of Headache That Common and Preventable.

Authors:  Elif Kocasoy Orhan; Betül Baykan
Journal:  Noro Psikiyatr Ars       Date:  2013-08-01       Impact factor: 1.339

3.  Psychiatric comorbidity and suicide risk in patients with chronic migraine.

Authors:  Maurizio Pompili; Gianluca Serafini; Daniela Di Cosimo; Giovanni Dominici; Marco Innamorati; David Lester; Alberto Forte; Nicoletta Girardi; Sergio De Filippis; Roberto Tatarelli; Paolo Martelletti
Journal:  Neuropsychiatr Dis Treat       Date:  2010-04-07       Impact factor: 2.570

Review 4.  Medication overuse headache.

Authors:  Zaza Katsarava; Dagny Holle; Hans-Christoph Diener
Journal:  Curr Neurol Neurosci Rep       Date:  2009-03       Impact factor: 5.081

Review 5.  A narrative review on the management of medication overuse headache: the steep road from experience to evidence.

Authors:  Paolo Rossi; Rigmor Jensen; Giuseppe Nappi; Marta Allena
Journal:  J Headache Pain       Date:  2009-10-03       Impact factor: 7.277

6.  Psychometric properties of the stagnation scale in medication overuse headache patients.

Authors:  Marco Innamorati; Maurizio Pompili; Denise Erbuto; Federica Ricci; Monica Migliorati; Dorian A Lamis; Mario Amore; Paolo Girardi; Paolo Martelletti
Journal:  J Headache Pain       Date:  2015-02-19       Impact factor: 7.277

Review 7.  Medication-overuse headache: a widely recognized entity amidst ongoing debate.

Authors:  Nicolas Vandenbussche; Domenico Laterza; Marco Lisicki; Joseph Lloyd; Chiara Lupi; Hannes Tischler; Kati Toom; Fenne Vandervorst; Simone Quintana; Koen Paemeleire; Zaza Katsarava
Journal:  J Headache Pain       Date:  2018-07-13       Impact factor: 7.277

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.